FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791779516> ?p ?o ?g. }

• W2791779516 endingPage "1262" @default.
• W2791779516 startingPage "1255" @default.
• W2791779516 abstract "Sclerotic chronic graft vs. host disease (cGVHD) still has a large impact on morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We performed the first prospective study to test whether sequential therapy of the anti-CD20 antibody rituximab followed by 6 months treatment with tyrosine kinase inhibitor nilotinib is a favorable treatment strategy for patients with sclerotic cGVHD. Twenty-nine patients were included, 24 were available for analysis. We observed objective responses in 71% of patients (two patients CR, 15 patients PR). Moreover, two out of five patients suffering from severe ulcerations showed complete resolution of ulcers. Observed responses lasted until the end of study follow-up. The majority of responding patients could reduce daily corticosteroid dose with more than 50%. Furthermore, CD5+ B-cells are significantly lower (p = 0.007) in responding patients at baseline, proposing a new biomarker predictive for response. In conclusion, sequential treatment of rituximab followed by nilotinib associates with a very high response rate in this difficult to treat patient population. CD5+ B-cells could assist in guiding treatment choices and might be a first step toward more personalized cGVHD treatment. This trial was registered at the Dutch clinical trial registry as NTR1222." @default.
• W2791779516 created "2018-03-29" @default.
• W2791779516 creator A5033210828 @default.
• W2791779516 creator A5036769821 @default.
• W2791779516 creator A5038147858 @default.
• W2791779516 creator A5048440121 @default.
• W2791779516 creator A5048950666 @default.
• W2791779516 creator A5050973811 @default.
• W2791779516 creator A5056738351 @default.
• W2791779516 creator A5060932751 @default.
• W2791779516 creator A5061889892 @default.
• W2791779516 creator A5062168279 @default.
• W2791779516 creator A5071204393 @default.
• W2791779516 creator A5073604089 @default.
• W2791779516 creator A5082846328 @default.
• W2791779516 creator A5083027485 @default.
• W2791779516 creator A5087024958 @default.
• W2791779516 date "2018-03-16" @default.
• W2791779516 modified "2023-10-06" @default.
• W2791779516 title "Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib" @default.
• W2791779516 cites W1870543278 @default.
• W2791779516 cites W2011790916 @default.
• W2791779516 cites W2013426040 @default.
• W2791779516 cites W2019419625 @default.
• W2791779516 cites W2029503621 @default.
• W2791779516 cites W2037845887 @default.
• W2791779516 cites W2039904206 @default.
• W2791779516 cites W2041548911 @default.
• W2791779516 cites W2060306720 @default.
• W2791779516 cites W2078964293 @default.
• W2791779516 cites W2082495301 @default.
• W2791779516 cites W2109346271 @default.
• W2791779516 cites W2110395869 @default.
• W2791779516 cites W2117206796 @default.
• W2791779516 cites W2123868466 @default.
• W2791779516 cites W2124196948 @default.
• W2791779516 cites W2135221579 @default.
• W2791779516 cites W2138298776 @default.
• W2791779516 cites W2148922588 @default.
• W2791779516 cites W2209448786 @default.
• W2791779516 cites W2216107281 @default.
• W2791779516 cites W2233354089 @default.
• W2791779516 cites W2234309584 @default.
• W2791779516 cites W2379365975 @default.
• W2791779516 cites W2424060136 @default.
• W2791779516 cites W2460270380 @default.
• W2791779516 cites W2595371676 @default.
• W2791779516 cites W2618073389 @default.
• W2791779516 cites W2751352003 @default.
• W2791779516 cites W2754850852 @default.
• W2791779516 doi "https://doi.org/10.1038/s41409-018-0158-9" @default.
• W2791779516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29549292" @default.
• W2791779516 hasPublicationYear "2018" @default.
• W2791779516 type Work @default.
• W2791779516 sameAs 2791779516 @default.
• W2791779516 citedByCount "11" @default.
• W2791779516 countsByYear W27917795162018 @default.
• W2791779516 countsByYear W27917795162019 @default.
• W2791779516 countsByYear W27917795162020 @default.
• W2791779516 countsByYear W27917795162021 @default.
• W2791779516 countsByYear W27917795162022 @default.
• W2791779516 countsByYear W27917795162023 @default.
• W2791779516 crossrefType "journal-article" @default.
• W2791779516 hasAuthorship W2791779516A5033210828 @default.
• W2791779516 hasAuthorship W2791779516A5036769821 @default.
• W2791779516 hasAuthorship W2791779516A5038147858 @default.
• W2791779516 hasAuthorship W2791779516A5048440121 @default.
• W2791779516 hasAuthorship W2791779516A5048950666 @default.
• W2791779516 hasAuthorship W2791779516A5050973811 @default.
• W2791779516 hasAuthorship W2791779516A5056738351 @default.
• W2791779516 hasAuthorship W2791779516A5060932751 @default.
• W2791779516 hasAuthorship W2791779516A5061889892 @default.
• W2791779516 hasAuthorship W2791779516A5062168279 @default.
• W2791779516 hasAuthorship W2791779516A5071204393 @default.
• W2791779516 hasAuthorship W2791779516A5073604089 @default.
• W2791779516 hasAuthorship W2791779516A5082846328 @default.
• W2791779516 hasAuthorship W2791779516A5083027485 @default.
• W2791779516 hasAuthorship W2791779516A5087024958 @default.
• W2791779516 hasBestOaLocation W27917795161 @default.
• W2791779516 hasConcept C126322002 @default.
• W2791779516 hasConcept C141071460 @default.
• W2791779516 hasConcept C143998085 @default.
• W2791779516 hasConcept C188816634 @default.
• W2791779516 hasConcept C2777408962 @default.
• W2791779516 hasConcept C2777413986 @default.
• W2791779516 hasConcept C2777583451 @default.
• W2791779516 hasConcept C2778729363 @default.
• W2791779516 hasConcept C2779338263 @default.
• W2791779516 hasConcept C2779972918 @default.
• W2791779516 hasConcept C2780653079 @default.
• W2791779516 hasConcept C2908647359 @default.
• W2791779516 hasConcept C2911091166 @default.
• W2791779516 hasConcept C71924100 @default.
• W2791779516 hasConcept C90924648 @default.
• W2791779516 hasConcept C99454951 @default.
• W2791779516 hasConceptScore W2791779516C126322002 @default.
• W2791779516 hasConceptScore W2791779516C141071460 @default.
• W2791779516 hasConceptScore W2791779516C143998085 @default.

• next